Our Services
X-Chem Services Empower Your Drug Discovery Strategy Our DNA-encoded library (DEL) expertise, medicinal chemistry experience and artificial intelligence innovations position...
X‑Chem Enters into Multitarget Oncology Discovery Research Collaboration and License Agreement with Genentech
Collaboration Includes Licensing of Preclinical Small Molecule Program WALTHAM, Mass.; Feb. 2, 2021 (Business Wire) – X-Chem, Inc., a global...
X‑Chem further expands Collaboration with Bayer to Discover Novel Medicines
WALTHAM, Mass. – October 3rd, 2017 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics based on an industry leading DNA-encoded library containing over 120 billion small molecules, and Bayer have further expanded their drug discovery collaboration across multiple therapeutic areas and target classes. The latest agreement with Bayer extends their access to X-Chem’s DEX™ technology by including the synthesis of custom Bayer DNA-Encoded Libraries and expanding the number of potential programs. The collaboration is focused on the discovery of innovative small molecule leads for complex drug targets in areas of high unmet medical need.
Consortium of X‑Chem, Harvard T.H. Chan School of Public Health and Other Leading Academic Institutions Wins Research Award from the Department of Defense
X-Chem, Inc., a privately held biotechnology company with a proprietary and innovative platform to generate small molecule therapeutics, today announced the award of a DOD CDMRP research grant entitled “Chemigenomic Drug Discovery for Tuberculosis.” The grant was awarded to a research consortium led by Eric Rubin, M.D., Ph.D., Irene Heinz professor of Immunology and Infectious Diseases at the Harvard T.H. Chan School of Public Health, and includes researchers from the University of Massachusetts, Worcester; the Joan & Sanford I. Weill Medical College of Cornell University; Rutgers, The State University of New Jersey; Texas A&M AgriLife Research; and X-Chem.
X‑Chem Expands Collaboration with Janssen in Inflammatory Diseases
WALTHAM, Mass. – February 15, 2017 – X-Chem, Inc. (X-Chem) announced today that it has expanded its collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover new drug leads for the treatment of inflammatory disease. The multi-target expansion builds on the parties’ existing discovery and license partnership, entered into in December 2014, and was facilitated by Johnson & Johnson Innovation. This latest agreement will apply X-Chem’s DEX™ platform to the identification of novel modulators for challenging disease targets, following the licensing of multiple series of X-Chem-discovered small molecules by Janssen in 2016. Under the terms of the agreement, X-Chem receives upfront payment and research funding, and is eligible to receive additional payments and royalties based on the achievement of clinical, regulatory and commercial milestones.
Servier and X‑Chem Announce Drug Discovery Collaboration in Neurological Diseases
Paris and Waltham, Mass.; Jan. 6, 2021 (Business Wire) – Servier, a global pharmaceutical Group and X-Chem, Inc., a privately...